Can-Fite BioPharma Ltd. (CANF) and Xenetic Biosciences Inc. (NASDAQ:XBIO) Comparing side by side.

As Biotechnology companies, Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) and Xenetic Biosciences Inc. (NASDAQ:XBIO) are our subject to compare. And more specifically their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Can-Fite BioPharma Ltd. 3.62M 6.82 4.84M -0.26 0.00 Xenetic Biosciences Inc. 7.50M 2.55 1.22M -0.12 0.00 In table 1 we can see Can-Fite BioPharma Ltd. and Xenetic Biosciences Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 has Can-Fite BioPharma Ltd. and Xenetic Biosciences Inc.’s net margins, return on equity (ROE) and return on assets.

Insider and Institutional Ownership

Can-Fite BioPharma Ltd. and Xenetic Biosciences Inc. has shares held by institutional investors as follows: 7.76% and 0.8%. Comparatively, Xenetic Biosciences Inc. has 64.63% of it’s share held by insiders.


On 6 of the 9 factors Xenetic Biosciences Inc. beats Can-Fite BioPharma Ltd..

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company’s lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of biologic drugs and orphan oncology therapeutics. Its lead proprietary technology is PolyXen, a platform technology for biologic drug delivery. The companyÂ’s lead drug candidate is XBIO-101, a small-molecule immunomodulator and interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer. It also develops OncoHist for the treatment of acute myeloid leukemia. The company has a research, development, license, and supply agreement with Shire plc to develop SHP656, a polysialylated recombinant (rFVIII) protein to treat hemophilia; and a collaborative research and development license agreement with PJSC Pharmsynthez to develop, commercialize and market PulmoXen for the treatment of cystic fibrosis, as well as Xemys for the treatment of multiple sclerosis. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts.

Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *